Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2012. The report details a specific share repurchase transaction executed on June 13, 2012, pursuant to shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 1,500,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,466.5 pence per share; lowest price paid was 1,452.0 pence per share.
- Treasury Holdings (Settled): 459,557,927 shares (8.41% of total issued share capital).
- Treasury Holdings (Including Unsettled): 464,107,927 shares (9.27% of current total voting rights).
- Shares in Issue (Excluding Treasury): 5,005,863,059 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the repurchase of 1,500,000 shares. Consequently, the percentage of shares held in Treasury increased to 8.41% of issued capital and 9.27% of total voting rights when including unsettled transactions.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It is a compliance disclosure regarding share buybacks and voting rights calculations under the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,005,863,059) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (459,557,927 settled) for assessing dilution or buyback program progress.
- Note that the 9.27% voting rights figure includes shares purchased but not yet settled.